Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2024-11-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before
hematopoietic stem cell transplant in treating patients with accelerated/blast phase
myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Ruxolitinib and fedratinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells
in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When
the healthy stem cells from a donor are infused into the patient they may help the patient's
bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated
stem cells may also replace the patient's immune cells and help destroy any remaining cancer
cells. Decitabine, with ruxolitinib or fedratinib, may work better than multi-agent
chemotherapy or no pre-transplant therapy, in treating patients with accelerated/blast phase
myeloproliferative neoplasms.